Remy B. Verheijen

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Lecia V. Sequist, Ji‐Youn Han, Myung‐Ju Ahn et al. · The Lancet Oncology · 2020 · 413 citations · Full text

Medicine, Oncology, Pharmacology +15

Efficacy of Savolitinib vs Sunitinib in Patients With<i>MET</i>-Driven Papillary Renal Cell Carcinoma

Toni K. Choueiri, Daniel Y.C. Heng, Jae‐Lyun Lee et al. · JAMA Oncology · 2020 · 179 citations · Full text

Medicine, Oncology, Pharmacology +13

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

Natasha B. Leighl, Hiroaki Akamatsu, Sun Min Lim et al. · Journal of Clinical Oncology · 2024 · 114 citations · Full text

Medicine, Oncology, Pharmacology +16

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

Remy B. Verheijen, Sander Bins, Ron H.J. Mathijssen et al. · Clinical Cancer Research · 2016 · 79 citations

Pharmacy, Oncology, Pharmacology +15

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

Maja J.A. de Jonge, Neeltje Steeghs, Martijn P. Lolkema et al. · Targeted Oncology · 2019 · 75 citations · Full text

Medicine, Oncology, Pharmacology +17